The Bank of England injected a record 122.9 billion pounds in a single week; the balance sheet reduction process has created a liquidity gap, leading banks to compete for short-term funds.
- The Bank of England announced on Thursday that it allocated a record £122.918 billion in seven-day funds through its weekly short-term repo operations, surpassing the previous record of £114.888 billion set last month. The central bank is increasingly relying on short-term repo operations to provide reserves to banks, while gradually reducing its holdings of government bonds accumulated under the quantitative easing programme.
- From a market sentiment perspective, the record repo demand indicates that, as the central bank’s balance sheet reduction progresses, the banking system is facing increasing reserve pressure. The ongoing reduction of quantitative easing bond holdings is forcing financial institutions to turn to the central bank’s short-term liquidity tools to fill funding gaps, leading to a significant rise in market reliance on central bank funds.
- This dynamic reflects a structural transformation underway in the money market. The previously abundant reserve-driven accommodative environment is gradually giving way to the tightening pressure brought by balance sheet reduction. By proactively injecting liquidity into the market through short-term repo operations, the Bank of England is essentially acting as the lender of last resort during the quantitative tightening process, aiming to prevent excessive reserve tightening from triggering severe volatility in the money market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
